Breadcrumb

[G09-01] Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

Overview

Overview

Commission: Commission awarded on 2009-12-17 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Health Economics
Current document:PDF Executive summary of the final report  [PDF, 293 kB]Further documents
Contact address:to the contact form

Report documents

Report documents

PublishedDocumentSizeType 
2013-10-30 Executive summary of the final report 293 kBPDFdownload file
2013-10-30 Final report (German version) 5 MBPDFdownload file
2013-10-30 Documentation and evaluation of comments on the preliminary report (German version) 2 MBPDFdownload file
2012-11-19 Executive summary of the preliminary report (German version) 318 kBPDFdownload file
2012-11-19 Preliminary report (German version) 5 MBPDFdownload file
2012-11-19 Annex 1 to the preliminary report (German version) 635 kBPDFdownload file
Note:

Calculation tool for determining costs

2012-11-19 Annex 2 to the preliminary report (German version) 27 kBZIPdownload file
Note:

Cost-benefit assessment model (TreeAge file)

2011-05-17 Report plan version 1.0 (German version) 432 kBPDFdownload file
2011-05-17 Documentation and appraisal of comments on the preliminary report plan (German version) 4 MBPDFdownload file
2010-10-26 Preliminary report plan (German version) 371 kBPDFdownload file


At a glance


Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close